Welcome to the e-CCO Library!

DOP074: Incidence prediction of fistula formation in England
Year: 2016
Source: ECCO'16 DOP
Authors: Sahnan K.
environmental factors, perianal fistulae, non-perianal fistulae, Crohn's Disease
Files: 1
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in Ulcerative Colitis patients
Year: 2017
Source: ECCO'17 Barcelona
Authors: Mukherjee A.
Therapeutic drug monitoring, Pharmacokinetics, Tofacitinib
Files: 1
DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mukherjee A.*1, D'Haens G.R.2, Sandborn W.J.3, Tsuchiwata S.4, Vong C.5, Deng C.6, Xie R.6, Hazra A.1, Martin S.W.5, Friedman G.7, Niezychowski W.7, Su C.7

Created: Wednesday, 20 February 2019, 10:36 AM
DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.J. Dart1,2,3*, P. Vantourout1,2, A. Laing1,2, J. Digby-Bell3, N. Powell3,4, P. Irving3, A. Hayday1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

D'Haens G.1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13, Vermeire S.*14

Created: Wednesday, 20 February 2019, 10:36 AM
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
Year: 2016
Source: ECCO'16 DOP
Authors: Peyrin-Biroulet L.
disease activity indices, Crohn's Disease, Ulcerative Colitis, functional symptoms, disability
Files: 1
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panel
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Siegel1, C. Whitman2, B. Spiegel2, B. Feagan3, B. Sands4, E. Loftus5, R. Panaccione6, G. D’Haens7, C. Bernstein8, R. Gearry9, S. Ng10, G. Mantzaris11, B. Sartor12, M. Silverberg13, R. Riddell13, I. Koutroubakis14, C. O’Morain15, P. Lakatos16, D. McGovern2, J. Halfvarson17, W. Reinisch18, G. Rogler19, W. Kruis20, C. Tysk17, S. Schreiber21, S. Danese22, W. Sandborn23, A. Griffiths24, B. Moum25, C. Gasche26, F. Pallone27, S. Travis28, J. Panes29, J.-F. Colombel4, S. Hanauer30, L. Peyrin-Biroulet*31

Created: Friday, 22 February 2019, 9:49 AM
DOP076: A Danish cross-sectional study: Autoimmune and chronic inflammatory disorders associated with Ulcerative Colitis.
Year: 2016
Source: ECCO'16 DOP
Authors: Koch Hansen L.
ASSOCIATED AUTOIMMUNE DISEASE
Files: 1
DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Halling1, T. Knudsen2, J. Kjeldsen1, J. Nielsen3, L. Koch Hansen*4

Created: Friday, 22 February 2019, 9:49 AM
DOP076: A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sands B.*1, Sandborn W.2, Feagan B.G.3, Lichtenstein G.4, Zhang H.5, Szapary P.5, Panes J.6, Vermeire S.7, O'Brien C.5, Dewey J.5, Yang Z.5, Johanns J.5, Strauss R.5, Marano C.5

Created: Wednesday, 20 February 2019, 10:36 AM
DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Zundler*, M. Spocinska, V. Popp, E. Becker, R. Atreya, C. Neufert, I. Atreya, B. Weigmann, M.F. Neurath

Created: Thursday, 21 February 2019, 9:14 AM
DOP077: Deep immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Walshe*, L.A. Elliott, D. Danso-Abeam, G. Cullen, J. Sheridan, H. Mulcahy, E. Ryan, G. Doherty

Created: Thursday, 21 February 2019, 9:14 AM
DOP077: Immunochip Analysis Identifies Multiple Susceptibility Loci for Collagenous Colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Roda G.
Microscopic colitis
Files: 1
DOP077: Immunochip analysis identifies multiple susceptibility loci for collagenous colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Roda*1, H. Jianzhong2, Z. Zhongyang3, J. Torres1, A. Chen4, R. Petras5, D. Pardi6, A. Juga7, G. Levi3, W. Cao8, F. Rieder9, I. Gordon10, K. Hao3, N. Harpaz11, J. Cho12, J.-F. Colombel12, I. Peter3

Created: Friday, 22 February 2019, 9:49 AM
DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lee S.D.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Chiorean M.3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kühbacher T.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Peyrin-Biroulet L.3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP078: Risk of malignancy in paediatric inflammatory bowel disease: Results from the DEVELOP registry
Year: 2016
Source: ECCO'16 DOP
Authors: Veereman G.
Malignancy, mortality, anti-TNF agents
Files: 1